Kidney Week

Abstract: FR-OR109

Effect of Semaglutide on Mortality Outcomes in the FLOW Trial

Session Information

• Late-Breaking Science Orals - 1
  October 25, 2024 | Location: Room 6C, Convention Center
  Abstract Time: 05:00 PM - 05:10 PM

Category: CKD (Non-Dialysis)

• 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

• Pratley, Richard E., AdventHealth Translational Research Institute, Orlando, Florida, United States

Richard E. Pratley, MD

• Mahaffey, Kenneth W., Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Palo Alto, California, United States

Kenneth W. Mahaffey, MD

• Mann, Johannes F., KfH Kidney Centre, Munich, Germany

Johannes F. Mann, MD

• Tuttle, Katherine R., Division of Nephrology, University of Washington School of Medicine, Seattle, Washington, United States

Katherine R. Tuttle, MD, FASN

• Rossing, Peter, Steno Diabetes Center Copenhagen, Herlev, Denmark

Peter Rossing, MD, DrMed

• Idorn, Thomas, Novo Nordisk A/S, Søborg, Denmark

Thomas Idorn, MD, PhD

• David, Jens-Peter, Novo Nordisk A/S, Søborg, Denmark

Jens-Peter David, MSc, PhD

• Bosch-Traberg, Heidrun, Novo Nordisk A/S, Søborg, Denmark

Heidrun Bosch-Traberg, MD, DrMed

• Jeppesen, Ole K., Novo Nordisk A/S, Søborg, Denmark

Ole K. Jeppesen, MSc

• Bax, Willem A., Medical Centre Alkmaar, Alkmaar, Netherlands

Willem A. Bax, MD, PhD

• Gillard, Pieter, Department of Endocrinology, University Hospitals Leuven - KU Leuven, Leuven, Belgium

Pieter Gillard, MD, PhD

• Arici, Mustafa, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Mustafa Arici, MD

• Shamkhalova, Minara, Department of Diabetic Kidney Disease, Endocrinology Research Centre, Moscow, Russian Federation

Minara Shamkhalova

• Perkovic, Vlado, University of New South Wales, Sydney, New South Wales, Australia

Vlado Perkovic, MBBS, PhD, FASN

Group or Team Name

• FLOW Trial Committees and Investigators.

Background

In FLOW, semaglutide 1.0 mg (sema) reduced the risk of major kidney and cardiovascular (CV) events. Here, we assess the effect of sema on mortality outcomes.

Methods

Participants (≥18 years with T2D and CKD) were randomized 1:1 to receive once-weekly subcutaneous sema or placebo. Cause of death was confirmed by an event adjudication committee.

Results

Compared with placebo, sema reduced the risk of all-cause death (HR [95% CI] 0.80 [0.67, 0.95]), CV death (0.71 [0.56, 0.89]), and death of undetermined cause (0.62 [0.42, 0.91]; Figures 1, 2). The most common causes of CV death were sudden cardiac death (2.8% sema vs 3.8%) placebo and heart failure (0.3% vs 0.7%). Sema had no effect on non-CV/non-kidney or kidney death. The most common causes of non-CV/non-kidney death were infection (3.3% vs 3.7%) and malignancy (1.4% vs 1.2%; Figure 2).

Conclusion

In FLOW, sema reduced the risk of all-cause and CV death by 20% and 29%, and death of undetermined cause by 38%, relative to placebo.

Funding

• Commercial Support – Novo Nordisk